Kapruvia (difelikefalin)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- difelikefalin
- Company
- Vifor Fresenius Medical Care Renal Pharma France
- Status
- Authorised
- Therapeutic area
- Pruritus
- CHMP opinion
- Thu 24 Feb 2022
- EU approval
- Mon 25 Apr 2022
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005612
- ATC
- V03AX
- Official record
- www.ema.europa.eu
Indication
Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Follow Kapruvia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.